A phase I/II trial of anti-CD22/CD19 CAR-T cell therapy, CART2219.1, in adult and pediatric relapsed/refractory B-ALL

In a multicenter phase I/II trial of 11 patients with relapsed or refractory B-lineage acute lymphoblastic leukemia who received tandem CD22/CD19 CAR T-cell therapy, all patients experienced complete remission by Day 28. Additionally, 91% of patients achieved minimal residual disease–negative status and encouraging long-term survival outcomes without consolidative transplantation.